SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

TELA

TELA Bio, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and slowing U.S. revenue growth (unit growth of 13% but revenue only +3% due to mix) are concerning. Watch for Q2 revenue guidance of $20M, if achieved, it would imply ~5% YoY growth, still below the full-year 8% target. Monitor cash burn trajectory; at current rate, cash runway is ~3 quarters without additional financing.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9600
T+0 close · May 12, 2026 · via day close
Latest settled
−9.39%
T+60 · $0.8699
Vs SPY
−13.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $0.9600entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $0.9600
  3. T+5 · 6mo ago −10.42%α −9.26% · $0.8600
  4. T+20 · 5mo ago −5.00%α −4.39% · $0.9120
  5. T+60 · 3mo ago −9.39%α −13.82% · $0.8699
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP), which is worse than the -$0.19 consensus estimate. The company reiterated full-year 2026 revenue guidance of at least 8% growth, but Q1 growth was only 3%, and net loss widened to $12.3M from $11.3M a year ago. The stock may face pressure from the EPS miss and decelerating revenue growth, partially offset by the reiterated guidance and European momentum.

Key Financial Metrics

EPS
−$0.21
est −$0.19 · -10.5%
Revenue
$19.1M
est $19.0M · +0.3% · +2.9% YoY
Rating
miss
Guidance
at least 8% growth over FY2025 (implied ~$82.5M+)
maintained
Gross Margin
65.7%

Key Facts

  • Q1 2026 revenue of $19.1M, +3% YoY (vs consensus $19.0M)
  • GAAP EPS of -$0.21 vs consensus -$0.19 (miss of 10.5%)
  • Net loss widened to $12.3M from $11.3M in Q1 2025
  • Gross margin declined to 65.7% from 67.6% due to higher excess inventory charges
  • Reiterated full-year 2026 revenue guidance of at least 8% growth
  • Q2 2026 revenue guided to ~$20.0M
  • Cash and equivalents of $39.5M, down from $50.8M at year-end 2025
  • European revenue grew 41% YoY; U.S. revenue growth was modest due to product mix headwinds

Financial Impact

Revenue beat consensus by ~$0.1M (0.5%), but EPS missed by $0.02 (10.5%). Net loss increased $1.0M YoY.

revenueepsnet lossgross margincash

Risk Factors

  • Cash burn: $11.3M in Q1, leaving ~3.5 quarters of runway at current pace
  • U.S. product mix headwinds pressuring revenue growth despite unit growth
  • GAAP EPS miss of 10.5% vs consensus may disappoint investors
  • Full-year 8% growth guidance requires acceleration from Q1's 3%

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293358

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026